Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis. A randomized multicenter study.

Eighty-two patients with community-acquired pneumonia (CAP) or acute exacerbation (AE) of chronic bronchitis were randomized to receive ofloxacin (OFL) 400 mg twice daily (39 patients) versus 400 mg once daily (43 patients) orally. Cure rates showed no statistically significant difference (90.1 vs.